Fingerprint
Dive into the research topics of 'Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: Response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): Study protocol of a phase II, open-label, multicenter study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically